CRISPR & Neurodegenerative Diseases: A New Hope?
# CRISPR Approach Yields New Insights into Alzheimer’s Disease and Other Neurodegenerative Conditions
The prestigious Byers Award for Basic Science, supported by the Program for Breakthrough Biomedical Research (PBBR) at UCSF, has fueled discoveries that have leveraged $1.81 billion in scientific research funding. This support is enabling researchers like martin Kampmann, PhD, to pioneer innovative approaches to understanding and combating devastating neurodegenerative diseases like Alzheimer’s.
## From Molecular Biology to Neuroscience: A New Understanding of Alzheimer’s
UCSF fosters a uniquely collaborative habitat where groundbreaking research can thrive. “UCSF is one of the few places in the world where innovative strategies are able to succeed because of the robust neuroscience community support,” says Kampmann. His work, initially focused on fundamental molecular processes, exemplifies the power of interdisciplinary collaboration in tackling complex biological challenges.
### Early Career and foundational Research
Kampmann’s journey began with studies in human biology and biochemistry in Germany and the UK,culminating in a doctorate at The Rockefeller University.His early research centered on the intricate movement of molecules within cells – a critical process for cellular function.This foundational work laid the groundwork for his later investigations into the genetic underpinnings of neurological disorders.
### Leveraging CRISPR Technology at UCSF
arriving at UCSF for postdoctoral training under Jonathan weissman, PhD, Kampmann seized the chance to apply newly developed CRISPR technology to his research. He spearheaded the creation of a CRISPR-based genetic screening platform, allowing scientists to systematically study genes across the human genome and identify those crucial to specific cellular processes.
“The timing was great as CRISPR technology was just being developed by [UC Berkeley biochemist and Nobel laureate] Jennifer Doudna,” Kampmann explains. “We were able to take advantage of these exciting new technologies to build a platform that allowed us to systematically study genes across the human genome. The purpose was to identify which genes play critically important roles in specific cellular processes and better understand their functions.”
### Identifying Key Molecules in Alzheimer’s Disease
This innovative platform proved instrumental in a collaborative project with the Memory and Aging center’s Neurodegenerative Disease Brain Bank, led by Lea Grinberg MD, PhD, and William Seeley MD. Together, the team employed advanced genetic research methods to pinpoint specific molecules present in the neurons most vulnerable to Alzheimer’s disease, specifically within the brain region exhibiting early signs of the condition.
This represents a significant breakthrough, offering a more targeted understanding of the molecular mechanisms driving the disease. By identifying these key molecules, researchers can begin to develop more effective therapies aimed at preventing or slowing the progression of Alzheimer’s.
### The Power of Collaboration and a Bold Research Culture
Kampmann emphasizes the vital role of UCSF’s collaborative spirit in his success. “These kinds of partnerships ground our discoveries and make our models stronger,” he states. The university’s commitment to fostering a bold research culture, combined with access to unique resources like the Neurodegenerative Disease Brain Bank, creates an environment where ambitious projects can flourish. This collaborative approach is not only accelerating research into Alzheimer’s disease but also holds promise for unraveling the complexities of other neurodegenerative conditions.